WO2017110582A1

WO2017110582A1 - Composition for oral cavity

Info

Publication number: WO2017110582A1
Application number: PCT/JP2016/087054
Authority: WO
Inventors: 祐輔吉田; 更石動
Original assignee: ライオン株式会社
Priority date: 2015-12-25
Filing date: 2016-12-13
Publication date: 2017-06-29
Also published as: JPWO2017110582A1

Abstract

A composition for the oral cavity that shows excellent retention and absorption properties of an ascorbic acid phosphate ester or a salt thereof in the mucous membranes in the oral cavity, said composition containing (A) 0.1-5 mass% of an ascorbic acid phosphate ester or a salt thereof, and (B) 0.1-4 mass% of an acyltaurine salt and/or an acylglutamic acid salt, preferably together with (C) a specific polyoxyethylene alkyl ether. A method for improving, in a composition for the oral cavity containing component (A), the retention and absorption properties of component (A) in the mucous membranes in the oral cavity, said method comprising adding, to the composition for the oral cavity, component (B) preferably together with component (C). An agent for improving the retention and absorption properties of component (A) in the mucous membranes in the oral cavity, said agent being to be added to a composition for the oral cavity containing component (A) and containing component (B) preferably together with component (C). Use of component (B) preferably together with component (C) in a composition for the oral cavity containing component (A).

Description

Oral composition

The present invention relates to a composition for oral cavity with improved retention and absorption of ascorbic acid phosphate ester or a salt thereof in the oral mucosa.

Ascorbic acid plays an important role in the expression of enzyme activity in the body and is known to have a variety of physiological activities. In particular, it acts as a coenzyme for prolyl and lysyl hydroxylase and is essential for collagen synthesis. ing. For this reason, it is useful for the prevention and treatment of gingivitis and periodontitis associated with collagen destruction, and various ascorbic acid derivatives have been developed in the past, especially ascorbic acid esters and salts thereof have been used in oral compositions. It has been.

Patent Documents 1 to 7 propose techniques for oral compositions containing ascorbic acid esters and salts thereof.

JP 2009-149537 A JP 2014-5212 A JP 2004-323488 A JP 2011-6351 A International Publication No. 2010/143589 JP 2013-129601 A JP 2005-239655 A

However, the oral cavity is different from the skin in that saliva is always supplied and wet, and it is often rinsed with water after applying the formulation, so that water-soluble components stay on the wet gingival surface or inside the gingiva. Or in an environment where absorption is difficult. For this reason, in the composition for oral cavity, there existed a problem that the retentivity to the gingival surface of the ascorbic acid ester and its salt, and the absorptivity to the inside of gingiva were not enough.

The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an oral composition that is excellent in retention and absorbability of ascorbic acid phosphate ester or a salt thereof in the oral mucosa.

As a result of intensive studies to achieve the above object, the present inventors have (B) acyl taurine salt and / or acyl glutamic acid in (A) an oral composition containing ascorbic acid phosphate or a salt thereof. It has been found that when salt is added, the retention and absorbability of the component (A) in the oral mucosa are improved, and a remarkable effect is obtained with respect to the above problems, and the present invention has been made.

That is, in the composition for oral cavity, the retention and absorbability of ascorbic acid ester or a salt thereof in the oral mucosa is not sufficient, and the conventional technique could not satisfactorily improve the retention and absorbability. Then, by blending a specific amount of the component (B), the retention and absorption of the component (A) in the oral mucosa are remarkably improved, and thereby, an anionic interface generally blended in the oral composition. It is a simple formulation of the active agent sodium lauryl sulfate or sodium lauroyl sarcosine, and provides a specific and exceptional effect that cannot be achieved when the component (B) is not added. In this case, the water-soluble (A) ascorbic acid phosphate ester or a salt thereof is particularly difficult to stay and absorb in the oral mucosa, which is mostly wet with saliva or water, When the component (A) is combined with the component (B), the retention / absorption rate is improved by 20% or more in the test using mouse skin as shown in the experimental examples described later, as compared to the case of the component (A) alone. It is possible to impart exceptionally excellent retention and absorbency.
Furthermore, in the present invention, in addition to the component (B), (C) a polyoxyethylene alkyl ether having an alkyl group having 12 to 22 carbon atoms and an average added mole number of ethylene oxide of 10 to 50 is combined. As a result, the retention and absorption of the component (A) in the oral mucosa are further improved, and oral irritation can be sufficiently suppressed.

Accordingly, the present invention provides the following oral compositions and methods for improving the retention and absorbability of ascorbic acid phosphates or salts thereof in the oral mucosa in the oral compositions described below.
[1]
(A) Ascorbic acid phosphate ester or salt thereof 0.1 to 5% by mass,
(B) Acyl taurate and / or acyl glutamate 0.1-4% by mass
A composition for oral cavity, comprising:
[2]
The oral composition according to [1], wherein the component (B) is an acyl taurine salt and / or an acyl glutamate whose acyl group has 10 to 20 carbon atoms.
[3]
The composition for oral cavity according to [2], wherein the component (B) is sodium lauroylmethyl taurate and / or sodium lauroyl glutamate.
[4]
The composition for oral cavity according to any one of [1] to [3], wherein (B) / (A) is 0.1 to 15 in terms of mass ratio.
[5]
Further, (C) 0.1 to 4% by mass of a polyoxyethylene alkyl ether having an alkyl group having 12 to 22 carbon atoms and an average addition mole number of ethylene oxide of 10 to 50 is contained [I] to [4 ] The composition for oral cavity in any one of.
[6]
The composition for oral cavity according to [5], wherein (B) / (C) is 0.1 to 12 as a mass ratio.
[7]
The oral composition according to any one of [1] to [6], which is a dentifrice.
[8]
The composition for oral cavity according to any one of [1] to [6], which is a mouthwash.
[9]
(A) 0.1B to 4% by mass of (B) acyl taurine salt and / or acyl glutamate is added to the oral composition containing 0.1 to 5% by mass of ascorbic acid phosphate or a salt thereof. A method for improving retention and absorbability of (A) an ascorbic acid phosphate ester or a salt thereof in the oral cavity composition in the oral cavity composition.
[10]
(B) / (A) is 0.1 to 15 in terms of mass ratio, and (A) ascorbic acid phosphate or salt thereof in the oral mucosa and absorbability in the oral composition according to [9] How to improve.
[11]
In addition to the component (B), 0.1 to 4% by mass of (C) polyoxyethylene alkyl ether having an alkyl group with 12 to 22 carbon atoms and an average added mole number of ethylene oxide of 10 to 50 is blended. [9] A method for improving retention and absorbability of (A) ascorbic acid phosphate ester or a salt thereof in the oral composition of [9] or [10].
[12]
(B) / (C) is 0.1 to 12 in terms of mass ratio, and (A) ascorbic acid phosphate or salt thereof in the oral mucosa and absorbability in the oral composition according to [11] How to improve.

[13]
(A) Ascorbic acid phosphate containing (B) acyl taurine salt and / or acyl glutamate for blending oral composition containing 0.1-5% by mass of ascorbic acid phosphate or salt thereof An agent for improving retention and absorption of an ester or a salt thereof in the oral mucosa, and blended in the oral composition so that the amount of the component (B) is 0.1 to 4% by mass of the whole composition. (A) The ascorbic acid phosphate ester or a salt thereof in the oral mucosa and the absorbability improver.
[14]
The retention and absorbency improver according to [13], wherein (B) / (A) is blended in the oral composition so that the mass ratio is 0.1 to 15.
[15]
And (C) polyoxyethylene alkyl ether having 12 to 22 carbon atoms in the alkyl group and an average addition mole number of ethylene oxide of 10 to 50, and (C) the amount of the component is 0.1% of the total composition. The retention and absorbency improver according to [13] or [14], which is added to the composition for oral cavity so as to be 4% by mass.
[16]
The retention and absorbency improver according to [15], wherein (B) / (C) is blended in the oral composition so that the mass ratio is 0.1 to 12.
[17]
(A) In order to improve the retention and absorbability of (A) ascorbic acid phosphate or a salt thereof in the oral mucosa in an oral composition containing 0.1 to 5% by mass of ascorbic acid phosphate or a salt thereof. (B) acyl taurine salt and / or acyl glutamate for the preparation of the preparation, wherein the amount of the component (B) used is 0.1 to 4% by mass of the total composition (B) Use of acyl taurine salt and / or acyl glutamate.
[18]
The use according to [17], wherein (B) / (A) is 0.1 to 15 in terms of mass ratio.
[19]
Use of the polyoxyethylene alkyl ether in which the component (B) and the (C) alkyl group have 12 to 22 carbon atoms and the average added mole number of ethylene oxide is 10 to 50, and the use of the component (C) Use according to [17] or [18], wherein the amount is from 0.1 to 4% by weight of the total composition.
[20]
The use according to [19], wherein (B) / (C) is 0.1 to 12 as a mass ratio.
[21]
(A) In the composition for oral cavity containing 0.1 to 5% by mass of ascorbic acid phosphate ester or salt thereof (A) Ascorbic acid phosphate ester or salt thereof in the oral mucosa as an agent for improving retention and absorption (B) acyl taurine salt and / or acyl glutamate for use, wherein the amount of component (B) used is 0.1 to 4% by mass of the total composition (B) Acyl taurate and / or acyl glutamate for
[22]
(B) Acyl taurine salt and / or acyl glutamate for use according to [21], wherein (B) / (A) is 0.1 to 15 in terms of mass ratio.
[23]
A polyoxyethylene alkyl ether in which the component (B) and (C) the alkyl group have 12 to 22 carbon atoms and the average added mole number of ethylene oxide is 10 to 50 for the use, (B) acyl taurine salt and / or acyl glutamate salt and (C) alkyl group for use according to [21] or [22], wherein the amount of the component used is 0.1 to 4% by mass of the total composition Polyoxyethylene alkyl ether having 12 to 22 carbon atoms and an average addition mole number of ethylene oxide of 10 to 50.
[23]
(B) acyl taurine salt and / or acyl glutamate for use according to [23], wherein (B) / (C) is 0.1 to 12 in terms of mass ratio, and (C) the carbon number of the alkyl group is Polyoxyethylene alkyl ether having 12 to 22 and an average addition mole number of ethylene oxide of 10 to 50.

According to the present invention, it is possible to provide an oral composition having excellent retention and absorption of ascorbic acid phosphate or a salt thereof in the oral mucosa. Furthermore, in this invention, the improvement of the prevention or improvement effect of a periodontal disease can also be anticipated by the retention and absorption property to the oral mucosa of ascorbic acid phosphate ester or its salt.

Hereinafter, the present invention will be described in further detail. The composition for oral cavity of the present invention contains (A) an ascorbic acid phosphate or a salt thereof, (B) an acyl taurine salt and / or an acyl glutamate.

(A) Ascorbic acid phosphate or a salt thereof, ascorbic acid, one, or two or more of the hydroxyl groups at the 2nd, 3rd, 5th and 6th positions are converted to phosphates, for example, L-ascorbic acid-2-phosphate ester, L-ascorbic acid-3-phosphate ester, L-ascorbic acid-6-phosphate ester, etc., and salts thereof include sodium salt, potassium salt, A calcium salt, a magnesium salt, etc. are mentioned. One kind selected from these ascorbic acid phosphates and salts thereof can be used alone or in combination of two or more. Among them, from the viewpoint of the stability of the composition, a derivative in which the hydroxyl group at the 2-position or 3-position of ascorbic acid is converted to a phosphate ester is preferable, and a magnesium salt or sodium salt of ascorbic acid-2-phosphate is more preferable. .

The blending amount of the ascorbic acid phosphate ester or salt thereof as component (A) is 0.1 to 5% (mass%, the same applies hereinafter) of the entire composition, preferably 0.2 to 2%. As the blending amount increases, the effect of preventing and improving the periodontal disease of the component (A) is sufficiently exerted, but when it exceeds 5%, the feeling of use (astringency, bitterness, tastelessness) becomes worse.

(B) The acyl taurine salt and / or acyl glutamate is a retention and absorption improver for the component (A), and an acyl taurine salt and an acyl glutamate whose acyl group has 10 to 20 carbon atoms can be used. As these salts, alkali metal salts such as sodium and potassium are suitable. Of these, acyl taurine salts are preferred in terms of effect expression.

Specifically, acyl taurine salts include cocoyl methyl taurine sodium, cocoyl methyl taurine potassium, lauroyl methyl taurine sodium, stearoyl methyl taurine sodium, myristoyl methyl taurine sodium, oleoyl methyl taurine sodium, palmitoyl methyl taurine sodium, cocoyl taurine sodium. Can be mentioned. Examples of the acyl glutamate include sodium cocoyl glutamate, sodium lauroyl glutamate, sodium myristoyl glutamate, and sodium stearoyl glutamate.
As the component (B), one or two or more selected from these can be used. In particular, sodium lauroylmethyl taurate, sodium lauroyl glutamate, and particularly sodium lauroylmethyl taurate are preferred from the viewpoint of effect expression.

The blending amount of the acyl taurine salt and / or acyl glutamate as the component (B) is 0.1 to 4% of the whole composition, and preferably 0.2 to 3%. When the blending amount is less than 0.1%, the retention and absorbability of the component (A) are inferior. When it exceeds 4%, the retention and absorbability of the component (A) are lowered.

(B) / (A) indicating the blending ratio of the component (A) and the component (B) can be 0.02 to 40 as the mass ratio, preferably 0.1 to 15, Preferably it is 0.3 to 14, more preferably 0.5 to 10. Within this range, the retention and absorbability of the component (A) are more excellent.

In the present invention, it is preferable that (C) the polyoxyethylene alkyl ether in which the number of carbon atoms of the alkyl group and the average number of added moles of ethylene oxide are in a specific range, respectively. When the component (C) is combined with the component (B), the retention and absorption of the component (A) in the oral mucosa are further improved, and oral irritation can be suppressed.

The polyoxyethylene alkyl ether of component (C) has 12 to 22 carbon atoms in the alkyl group, and the average added mole number of ethylene oxide is 10 to 50, preferably 15 to 50, more preferably Is twenty.
Specific examples include polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene oleyl ether, polyoxyethylene stearyl ether, and polyoxyethylene behenyl ether, in which the average added mole number of ethylene oxide is within the above range. 1 type, or 2 or more types selected from these can be used. Among these, polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, and polyoxyethylene stearyl ether are preferable, and polyoxyethylene lauryl ether is more preferable from the viewpoint of no irritation in the oral cavity.

When the polyoxyethylene alkyl ether (C) is blended, the blending amount is preferably 0.1 to 4%, more preferably 0.2 to 3% of the entire composition. When 0.1% or more is blended, oral irritation is sufficiently suppressed, and when it exceeds 4%, oral irritation may occur.

Moreover, it is more preferable to mix | blend (B) and (C) component by a specific ratio, (B) / (C) which shows the mixture ratio of (B) component and (C) component is preferably as mass ratio. It is 0.1 to 12, more preferably 0.4 to 6. Within this range, the retention and absorption of component (A) and the absence of oral irritation are more excellent.

The dosage form and shape of the oral composition of the present invention are not particularly limited. For example, liquid (solution, emulsion, suspension, etc.), semi-solid (gel, cream, paste, etc.), solid (tablet, particulate agent) , Capsules, films, kneaded materials, molten solids, waxy solids, elastic solids, etc.), such as dentifrices (toothpaste, liquid toothpaste, liquid toothpaste, powder toothpaste, etc.), mouthwash It can be used as products of various dosage forms such as agents, coating agents, patches, mouth fresheners, foods (for example, chewing gum, tablet candy, candy, gummi, film, troche etc.). In particular, dentifrices (toothpastes, liquid dentifrices, liquid dentifrices) and mouthwashes are suitable, and dentifrices are more preferred.

In addition to the above-mentioned components, the oral composition of the present invention can be blended with known additive components depending on the shape, dosage form, etc. that can be used for the oral composition within a range not impairing the effects of the present invention. . Specifically for dentifrices, abrasives, binders, surfactants other than components (B) and (C), wetting agents, pigments, fragrances, sweeteners, active ingredients other than component (A), pH adjustment Agents can be added.

As abrasives, silica-based abrasives such as silica gel, precipitated silica, aluminosilicate, zirconosilicate, calcium pyrophosphate, calcium carbonate, aluminum hydroxide, alumina, magnesium carbonate, tribasic magnesium phosphate, zeolite, zirconium silicate, Examples thereof include hydroxyapatite and synthetic resin-based abrasives (the amount is usually 2 to 40%, particularly 10 to 25% of the total composition).

As binders, organic binders such as sodium carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylethylcellulose, methylcellulose, cationized cellulose and other cellulosic binders, xanthan gum, carrageenan, guar gum, alginic acid Examples thereof include sodium, montmorillonite, gelatin, sodium polyacrylate, and the like, and examples of the inorganic binder include gelling silica, gelling aluminum silica, bee gum, and laponite. 1-10%, especially 0.5-5%).

Specific examples of the surfactant include those shown below.
Anionic surfactant: Alkyl sulfate such as sodium lauryl sulfate and sodium myristyl sulfate, sodium dodecylbenzenesulfonate, hydrogenated coconut fatty acid monoglyceride sodium monosulfate, sodium lauryl sulfoacetate, sodium α-olefin sulfonate, etc. Agent: Nonionic surfactant such as distearylmethylammonium chloride, stearyldimethylbenzylammonium chloride: sugar alcohol fatty acid esters such as sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester, sucrose fatty acid ester, glycerin fatty acid ester, polyglycerin Polyhydric alcohol fatty acid ester such as fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyethylene glycol fatty acid ester Terionic, polyoxyethylene polyoxypropylene copolymers, polyoxyethylene alkylphenyl ethers, ether type activators such as polyoxyethylene hydrogenated castor oil, and zwitterionic surfactants such as fatty acid alkanolamides such as lauric acid diethanolamide N-alkyldiaminoethylglycine, such as 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolium betaine, N-lauryldiaminoethylglycine, N-myristyldiaminoethylglycine, N-alkyl-1-hydroxyethylimidazoline betaine When these surfactants and the like are blended, the blending amount is preferably 0.2 to 15%, particularly 0.5 to 10% of the whole composition. In addition, from the viewpoint of retention and absorption of the component (A) in the oral mucosa, an anionic surfactant such as an alkyl sulfate (such as sodium lauryl sulfate) may not be added, and the amount added may be a composition. It may be 0.8% or less of the whole, preferably 0.6% or less.

As the wetting agent, reduced starch saccharified product, sugar alcohol such as sorbit, xylitol, erythritol, propylene glycol, pentylene glycol, hexylene glycol, octylene glycol, polyethylene glycol having an average molecular weight of 200 to 6000, ethylene glycol, 1,3 -Examples include sugar alcohols such as butylene glycol and glycerin, and polyhydric alcohols (the amount is usually 5 to 50%, particularly 20 to 45% of the total composition).

Examples of the pigment include legal pigments such as Blue No. 1, Yellow No. 4, and Green No. 3, natural pigments such as caramel, and titanium oxide.

As fragrances, menthol, anethole, carvone, eugenol, limonene, n-decyl alcohol, citronellol, α-terpineol, citronellyl acetate, cineol, linalool, ethyl linalool, crocodile, thymol, spearmint oil, peppermint oil, lemon oil, orange Oil, sage oil, rosemary oil, cinnamon oil, pimento oil, cinnamon leaf oil, perilla oil, winter green oil, clove oil, eucalyptus oil and the like.
The blending amount of the fragrance is preferably 0.000001 to 2% of the entire composition.

Sweetening agents include saccharin sodium, aspartame, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidyl dihydrochalcone, perilartin and the like.

As an active ingredient, a nonionic fungicide such as isopropylmethylphenol, a cationic fungicide such as cetylpyridinium chloride, a fluorine-containing compound such as sodium fluoride, sodium monofluorophosphate, and the like as long as the effects of the present invention are not impaired. Examples include anti-inflammatory agents such as tranexamic acid and allantoin, enzymes such as dextranase, vitamins other than component (A), plant extracts, and the like. In addition, the said active ingredient can be mix | blended in an effective amount in the range which does not prevent the effect of this invention.

The pH (25 ° C.) of the composition of the present invention is preferably 6.5 to 9, more preferably 6.8 to 8.8, and particularly preferably 7.0 to 8.6. The pH may be adjusted using a pH adjuster, and examples of the pH adjuster include organic acids such as citric acid, lactic acid and malic acid and salts thereof, hydrochloric acid, sodium hydroxide, potassium hydroxide, disodium hydrogen phosphate, Examples include inorganic compounds such as sodium dihydrogen phosphate.

Since the present invention has the above characteristics,
(I) Containing (B) component for composition for oral cavity containing said (A) component, More preferably, it contains (C) component. Agent,
(II) Component (B) for producing a preparation for improving retention and absorption of the component (A) in the oral mucosa in the oral composition containing the component (A), preferably (B) And the use of component (C) (III) component (B) for retention in the oral mucosa of component (A) in the oral composition containing component (A) and use as an absorbency improver, Preferably, components (B) and (C) are provided. In addition, a suitable component, the compounding quantity of each component, a compounding ratio, etc. are the same as that of the said composition for oral cavity.

Hereinafter, although an Example, a comparative example, and a formulation example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to the following Example. In the following examples, “%” means “% by mass” unless otherwise specified.

[Examples and Comparative Examples]
Oral compositions (toothpastes) having the compositions shown in Tables 1 to 3 were prepared by a conventional method and evaluated by the following methods. The results are shown in the table.

(1) Method for evaluating retention / absorbability of ascorbic acid phosphate or salt thereof Place the skin of 7-week-old male hairless mouse (Japan SLC Co., Ltd .; Lab Skin) cut into a 1.5 cm square on a 6-well plate. Then, 5 mL of artificial saliva was added and allowed to stand for 2 hours. A glass frame is placed on the skin so that the permeation area (approximately 0.8 cm ² ) is constant, and 300 μL of a solution obtained by diluting the oral composition of Examples or Comparative Examples shown in the table with artificial saliva three times. Each was injected and allowed to stand for 5 minutes. Thereafter, the diluted solution was discarded, and 5 mL of water was added, followed by washing at 160 rpm for 1 minute using a shaker. The washing was repeated for a total of 2 times.
The washing solution was discarded, the skin was collected in a tube, 1 mL of ethanol (90%) was added, and extraction was performed with a vortex mixer for 5 minutes. The extract was collected, diluted 1-fold with purified water, and then ascorbic acid phosphate or a salt thereof was quantified by HPLC (high performance liquid chromatography) under the following test conditions.

(Used equipment)
Pump: JASCO Corporation, PU-980
・ Sample introduction part: KSP-100X, manufactured by Kyowa Precision Co., Ltd.
Detector: JASCO Corporation, UV-970
-Column thermostat: SCC-2100, manufactured by Senshu Kagaku Co., Ltd.
・ Eluent flow rate: 1 mL / min
(Test conditions)
The HPLC conditions for quantifying ascorbic acid phosphate ester or a salt thereof are as follows.
・ Detector: UV absorption photometer (measurement wavelength: 210 nm)
Column: CAPCELL PAK C18 MG-II S-3
-Column temperature: 40 ° C
Eluent: 0.2% phosphate buffer solution / 5% methanol aqueous solution mixture

(B) The composition for oral cavity which is the same composition except not containing (C) component and also (C) component (For example, in the case of the Example whose compounding quantity of (A) component is 0.3% of the comparative example 1) The retention / absorption rate of each example when the retention / absorption rate of ascorbic acid phosphate ester or a salt thereof was taken as 100% was calculated, and the retention / absorption property was determined according to the following criteria. From this result, the retention and absorbability of ascorbic acid phosphate or its salt in the oral mucosa were evaluated.
Evaluation criteria ◎: 150% or more ○: 120% or more and less than 150% △: 110% or more and less than 120% ×: Less than 110%

Moreover, the following method evaluated the absence of intraoral irritation of the composition for oral cavity (dentifrice) shown in Table 2. The results are shown in the table.

(2) Evaluation method of absence of intraoral irritation A sensory test was conducted using 10 expert panelists as evaluators. About 0.5 g of the oral composition was placed on a commercially available toothbrush and brushed for 3 minutes to evaluate the oral irritation felt during use. Sensory evaluation was performed according to the following four grades, the average value of the evaluation results of 10 persons was determined, and the absence of oral irritation was evaluated according to the following criteria. ○ The above were judged to be acceptable because of low oral irritation.
Score criteria:
4 points: No irritation.
3 points: There is almost no irritation.
2 points: There is some irritation.
1 point: There is considerable stimulation.
Evaluation criteria:
◎: 3.5 points or more and 4.0 points or less ○: 3.0 points or more and less than 3.5 points △: 2.0 points or more and less than 3.0 points ×: Less than 2.0 points

Details of the raw materials used are shown below. In addition, the number in () of polyoxyethylene alkyl ether is the average added mole number of ethylene oxide (the same applies hereinafter).
(A) L-ascorbyl magnesium phosphate: manufactured by Wako Pure Chemical Industries, Ltd. for biochemistry (B) sodium lauroylmethyl taurate:
Product name LMT-P, manufactured by Nikko Chemicals
(B) Sodium lauroyl glutamate:
Product name ALMS-P1 manufactured by Asahi Kasei Chemicals Corporation
(C) Polyoxyethylene (20) lauryl ether:
Product name EMALEX720, manufactured by Nippon Emulsion Co., Ltd.
Sodium lauryl sulfate (comparative product):
BASF Corporation, trade name Texapon OC-P

The following are examples of prescriptions. When an oral composition having the following composition was prepared and evaluated in the same manner as described above, the oral composition of the prescription example was excellent in the retention and absorption of ascorbic acid phosphate or a salt thereof. Moreover, intraoral irritation was suppressed.

[Prescription Example 1] Toothpaste (A) L-ascorbyl magnesium phosphate 0.3%
(B) Lauroylmethyl taurine sodium 1.2
(C) Polyoxyethylene (20) lauryl ether 1.5
Silicic anhydride 12
Sorbit liquid (70%) 40
Saccharin sodium 0.2
Thickening silica 6
Titanium oxide 0.5
Propylene glycol 3
Xanthan gum 0.7
Sodium polyacrylate 0.4
Citric acid 0.1
Sodium hydroxide 0.1
Fragrance 0.8
Purified water balance
Total 100.0%
(B) / (A) = 4
(B) / (C) = 0.8

[Prescription Example 2] Toothpaste (A) L-ascorbyl magnesium phosphate 0.2%
(B) Lauroylmethyl taurine sodium 1.2
(C) Polyoxyethylene (20) lauryl ether 2.0
Silicic anhydride 12
Sorbit liquid (70%) 40
Saccharin sodium 0.2
Thickening silica 6
Titanium oxide 0.5
Propylene glycol 3
Xanthan gum 0.7
Sodium polyacrylate 0.4
Citric acid 0.1
Sodium hydroxide 0.1
Fragrance 0.8
Purified water balance
Total 100.0%
(B) / (A) = 6
(B) / (C) = 0.6

[Prescription Example 3] Toothpaste (A) L-ascorbyl magnesium phosphate 2.0%
(B) Lauroylmethyl taurine sodium 1.2
(C) Polyoxyethylene (20) lauryl ether 1.5
Silicic anhydride 12
Sorbit liquid (70%) 40
Saccharin sodium 0.2
Thickening silica 6
Titanium oxide 0.5
Propylene glycol 3
Xanthan gum 0.7
Sodium polyacrylate 0.4
Citric acid 0.1
Sodium hydroxide 0.1
Fragrance 0.8
Purified water balance
Total 100.0%
(B) / (A) = 0.6
(B) / (C) = 0.8

[Prescription Example 4] Mouthwash (A) L-ascorbyl magnesium phosphate 0.3%
(B) Lauroylmethyl taurine sodium 0.2
(C) Polyoxyethylene (20) lauryl ether 0.5
Propylene glycol 3
Glycerin 4.5
Xylitol 3
Ethanol 2
Citric acid 0.015
Sodium citrate 0.12
Disodium monohydrogen phosphate 0.1
Fragrance 0.2
Purified water balance
Total 100.0%
(B) / (A) = 0.67
(B) / (C) = 0.4

Claims

(A) Ascorbic acid phosphate ester or salt thereof 0.1 to 5% by mass,
(B) Acyl taurate and / or acyl glutamate 0.1-4% by mass
A composition for oral cavity, comprising:
The oral composition according to claim 1, wherein the component (B) is an acyl taurine salt and / or an acyl glutamate having an acyl group having 10 to 20 carbon atoms.
The composition for oral cavity according to claim 2, wherein the component (B) is sodium lauroylmethyl taurate and / or sodium lauroyl glutamate.
The composition for oral cavity according to any one of claims 1 to 3, wherein (B) / (A) is 0.1 to 15 in terms of mass ratio.
Further, (C) 0.1 to 4% by mass of a polyoxyethylene alkyl ether having 12 to 22 carbon atoms of an alkyl group and an average addition mole number of ethylene oxide of 10 to 50 is contained. The composition for oral cavity of any one of Claims.
The composition for oral cavity according to claim 5, wherein (B) / (C) is 0.1 to 12 as a mass ratio.
The oral composition according to any one of claims 1 to 6, which is a dentifrice.
The oral composition according to any one of claims 1 to 6, which is a mouthwash.
(A) 0.1B to 4% by mass of (B) acyl taurine salt and / or acyl glutamate is added to the oral composition containing 0.1 to 5% by mass of ascorbic acid phosphate or a salt thereof. A method for improving retention and absorbability of (A) an ascorbic acid phosphate ester or a salt thereof in the oral cavity composition in the oral cavity composition.
The retention and absorption of (A) ascorbic acid phosphate or a salt thereof in the oral mucosa in the oral composition according to claim 9, wherein (B) / (A) is 0.1 to 15 in terms of mass ratio. How to improve.
In addition to the component (B), 0.1 to 4% by mass of (C) polyoxyethylene alkyl ether having an alkyl group with 12 to 22 carbon atoms and an average added mole number of ethylene oxide of 10 to 50 is blended. A method for improving retention and absorbability of (A) ascorbic acid phosphate or a salt thereof in the oral composition according to claim 9 or 10.
The retention and absorbability of (A) ascorbic acid phosphate or a salt thereof in the oral mucosa in the composition for oral cavity according to claim 11, wherein (B) / (C) is 0.1 to 12 as a mass ratio. How to improve.
(A) Ascorbic acid phosphate containing (B) acyl taurine salt and / or acyl glutamate for blending oral composition containing 0.1-5% by mass of ascorbic acid phosphate or salt thereof An agent for improving retention and absorption of an ester or a salt thereof in the oral mucosa, and blended in the oral composition so that the amount of the component (B) is 0.1 to 4% by mass of the whole composition. (A) The ascorbic acid phosphate ester or a salt thereof in the oral mucosa and the absorbability improver.
The retention and absorbency improver according to claim 13, wherein (B) / (A) is blended in the oral composition so that the mass ratio is 0.1 to 15.
And (C) polyoxyethylene alkyl ether having 12 to 22 carbon atoms in the alkyl group and an average addition mole number of ethylene oxide of 10 to 50, and (C) the amount of the component is 0.1% of the total composition. The retention and absorbency improver according to claim 13 or 14, which is added to the composition for oral cavity so as to be -4% by mass.
The retention and absorbency improver according to claim 15, wherein (B) / (C) is added to the oral composition so that the mass ratio is 0.1 to 12.
(A) In order to improve the retention and absorbability of (A) ascorbic acid phosphate or a salt thereof in the oral mucosa in an oral composition containing 0.1 to 5% by mass of ascorbic acid phosphate or a salt thereof. (B) acyl taurine salt and / or acyl glutamate for the preparation of the preparation, wherein the amount of the component (B) used is 0.1 to 4% by mass of the total composition (B) Use of acyl taurine salt and / or acyl glutamate.
The use according to claim 17, wherein (B) / (A) is 0.1 to 15 in terms of mass ratio.
Use of the polyoxyethylene alkyl ether in which the component (B) and the (C) alkyl group have 12 to 22 carbon atoms and the average added mole number of ethylene oxide is 10 to 50, and the use of the component (C) Use according to claim 17 or 18, wherein the amount is from 0.1 to 4% by weight of the total composition.
The use according to claim 19, wherein (B) / (C) is 0.1 to 12 as a mass ratio.